GH Research (GHRS) Consolidated Net Income (2020 - 2026)
GH Research (GHRS) posted quarterly Consolidated Net Income of -$14.3 million for Q4 2025, down 32.91% year-over-year from -$21.3 million in Q4 2024, and down 1.38% quarter-over-quarter from -$14.1 million in Q3 2025.
GH Research (GHRS) Consolidated Net Income (2020 - 2026) Analysis & Trends
GH Research's Consolidated Net Income history runs 6 years deep, the most recent figure standing at -$14.3 million for Q4 2025.
- In Q4 2025, Consolidated Net Income fell 32.91% year-over-year to -$14.3 million; the TTM figure through Dec 2025 stood at -$47.5 million (down 15.75% YoY), while the FY2025 annual figure was -$47.5 million, down 15.75% from the prior year.
- Consolidated Net Income for Q4 2025 stood at -$14.3 million, down from -$14.1 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$1.4 million in Q1 2021, with the low at -$14.5 million in Q4 2022.
- The 5-year median for Consolidated Net Income is -$8.9 million (2024), against an average of -$9.0 million.
- The sharpest annual moves came in 2021 and 2023: Consolidated Net Income plunged 10304.44% in 2021, then jumped 40.86% in 2023.
- GH Research's Consolidated Net Income stood at -$12.8 million in 2021, then slipped by 13.7% to -$14.5 million in 2022, then surged by 40.86% to -$8.6 million in 2023, then retreated by 25.17% to -$10.7 million in 2024, then plunged by 32.91% to -$14.3 million in 2025.
- Business Quant data shows GHRS's Consolidated Net Income at -$14.3 million in Q4 2025, -$14.1 million in Q3 2025, and -$8.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | -17.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.75 Mn |
| Dec 31, 2025 | -14.28 Mn |
| Sep 30, 2025 | -14.08 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Dec 31, 2024 | -10.74 Mn |
| Sep 30, 2024 | -10.49 Mn |
| Jun 30, 2024 | -10.83 Mn |
| Mar 31, 2024 | -8.96 Mn |
| Dec 31, 2023 | -8.58 Mn |
| Sep 30, 2023 | -7.43 Mn |
| Jun 30, 2023 | -7.79 Mn |
| Mar 31, 2023 | -9.26 Mn |
| Dec 31, 2022 | -14.51 Mn |
| Sep 30, 2022 | -6.91 Mn |
| Jun 30, 2022 | -6.72 Mn |
| Mar 31, 2022 | -8.02 Mn |
| Dec 31, 2021 | -12.76 Mn |
| Sep 30, 2021 | -4.68 Mn |
| Jun 30, 2021 | -2.61 Mn |